Should RCC immunotherapy continue after progression? – ModernMedicine
|
Should RCC immunotherapy continue after progression?
ModernMedicine Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma (RCC) may still derive benefit if continued on the immunotherapy agent after disease progression, according to a subgroup analysis of data from the phase III … |
